| The Zacks Analyst Blog Highlights: The Goldman Sachs Group, Lloyd's, Bank of ... - Zacks.com |
|
|
Zacks.com KAI-4169, the lead candidate at KAI Pharmaceuticals, is being evaluated for the treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients on dialysis. SHPT is a common and serious complication for the above patient |